Protein expression and functional analysis of the FHIT gene in human tumor cells

Journal of the National Cancer Institute

Volumn 90, Issue 6, 1998, Pages 426-432

  Otterson, Gregory A ^a   Xiao, Guang Hui ^b   Geradts, Joseph ^c   Jin, Fang ^b   Chen, Wei Dong ^a   Niklinska, Wieslawa ^a   Kaye, Frederic J ^a,d   Yeung, Raymond S ^b,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CARCINOMA CELL; CHROMOSOME 3P; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0032542701     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.6.426     Document Type: Article

References (30)

1. Lukeis R, Irving L, Garson M, Hasthorpe S. Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer 1990;2:116-24.
2. Whang-Peng J, Bunn PA Jr, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, et al. A nonrandom chromosomal abnormality, del 3p(14-23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 1982;6:119-34.
3. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, et al. Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer 1991;3:168-88.
4. Shimizu M, Yokota J, Mori N, Shuin T, Shinoda M, Terada M, et al. Introduction of normal chromosome 3p modulates the tumorigenicity of a human renal cell carcinoma cell line YCR. Oncogene 1990;5:185-94.
5. Anderson MJ, Stanbridge EJ. Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 1993;7:826-33.
6. Wang L, Paradee W, Mullins C, Shridhar R, Rosati R, Wilke CM, et al. Aphidicolin-induced FRA3B breakpoints cluster in two distinct regions. Genomics 1997;41:485-8.
7. Paradee W, Mullins C, He Z, Glover T, Wilke C, Opalka B, et al. Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. Genomics 1995;27:358-61.
8. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
9. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, et al. Fhit, a putative tumor suppressor in humans, is a di-nucleoside 5′,5″′-P1,P3-triphosphate hydrolase. Biochemistry 1996;35: 11529-35.
10. Lowenstein JM. Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. Nat Struct Biol 1997;4:231-8.
11. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997;57:504-12.
12. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci U S A 1996;93:9770-5.
13. Panagopoulos I, Thelin S, Mertens F, Mitelman F, Aman P. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer 1997;19: 215-9.
14. van den Berg A, Draaijers TG, Kok K, Timmer T, Van der Veen AY, Veldhuis PM, et al. Normal FHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chromosomes Cancer 1997;19:220-7.
15. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977;74:5463-7.
16. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
17. Qin XQ, Chittenden T, Livingston DM, Kaelin WG Jr. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 1992;6:953-64.
18. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996;85:17-26.
19. Sozzi G, Alder H, Tornielli S, Corletto V, Baffa R, Veronese ML, et al. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res 1996;56: 2472-4.
20. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, et al. FHIT mutations in human primary gastric cancer. Cancer Res 1997;57: 1435-7.
21. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996;56:3173-9.
22. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 1997;57:2112-5.
23. Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, Sarkar F, et al. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 1996;56:4347-50.
24. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-62.
25. Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997;57:2121-3.
26. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, et al. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996;56:2936-9.
27. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, et al. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res 1996;56:5579-82.
28. Zou TT, Lei J, Shi YQ, Yin J, Wang S, Souza RF, et al. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC). Oncogene 1997;15:101-5.
29. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997;57:4692-8.
30. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A 1997;94:13771-6.